Mirum Pharmaceuticals (MIRM) News Today $52.50 -0.66 (-1.24%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$52.44 -0.06 (-0.11%) As of 02/21/2025 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period FDA approves Mirum treatment for cerebrotendinous xanthomatosisFebruary 21 at 6:58 PM | markets.businessinsider.comUS FDA approves Mirum Pharma's genetic disorder drugFebruary 21 at 12:01 PM | reuters.comMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year High - Here's WhyMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 52-Week High - Should You Buy?February 20 at 3:40 PM | marketbeat.comMirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025February 19 at 4:04 PM | businesswire.comMirum Pharmaceuticals (MIRM) to Release Quarterly Earnings on WednesdayMirum Pharmaceuticals (NASDAQ:MIRM) will be releasing earnings before the market opens on Wednesday, February 26.February 19 at 3:06 AM | marketbeat.comEmpowered Funds LLC Purchases Shares of 33,266 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Empowered Funds LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 33,266 shares of the company's stoFebruary 17, 2025 | marketbeat.comMirum PharmaceuticalsFebruary 16, 2025 | forbes.comSG Americas Securities LLC Has $289,000 Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)SG Americas Securities LLC trimmed its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 66.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,978 shares of the companyFebruary 6, 2025 | marketbeat.comMirum Pharmaceuticals president sells $126,680 in stockFebruary 5, 2025 | msn.comInsider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 1,064 Shares of StockFebruary 5, 2025 | insidertrades.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells $51,306.08 in StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 1,064 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $51,306.08. Following the transaction, the senior vice president now owns 4,232 shares of the company's stock, valued at $204,067.04. The trade was a 20.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.February 4, 2025 | marketbeat.comPeter Radovich Sells 2,627 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) COO Peter Radovich sold 2,627 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $126,673.94. Following the completion of the transaction, the chief operating officer now owns 26,961 shares in the company, valued at $1,300,059.42. This represents a 8.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.February 4, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Sells $438,898.44 in StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 9,102 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $438,898.44. Following the transaction, the chief executive officer now directly owns 115,920 shares of the company's stock, valued at approximately $5,589,662.40. This trade represents a 7.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.February 4, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year High - Time to Buy?Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 1-Year High - Here's What HappenedFebruary 4, 2025 | marketbeat.comGolden State Equity Partners Increases Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Golden State Equity Partners increased its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 1,390.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,380 shares of the company's stock after acquirFebruary 3, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of "Buy" from AnalystsShares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have been assigned an average rating of "Buy" from the eleven research firms that are covering the firm, Marketbeat reports. Ten equities research analysts have rated the stock with a buy recommendation and one has assigned a sFebruary 3, 2025 | marketbeat.comMirum Pharmaceuticals stock soars to all-time high of $49.59January 31, 2025 | msn.comMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High - Time to Buy?Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year High - Time to Buy?January 29, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells $43,223.84 in StockJanuary 28, 2025 | insidertrades.comInsider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 902 Shares of StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 902 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $43,223.84. Following the sale, the senior vice president now directly owns 3,524 shares of the company's stock, valued at $168,870.08. The trade was a 20.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.January 27, 2025 | marketbeat.comInsider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells 3,177 Shares of StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) COO Peter Radovich sold 3,177 shares of the firm's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $152,241.84. Following the completion of the transaction, the chief operating officer now directly owns 29,588 shares of the company's stock, valued at approximately $1,417,856.96. The trade was a 9.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.January 27, 2025 | marketbeat.comChristopher Peetz Sells 6,837 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 6,837 shares of the business's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $327,629.04. Following the completion of the transaction, the chief executive officer now directly owns 125,022 shares of the company's stock, valued at approximately $5,991,054.24. This trade represents a 5.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.January 27, 2025 | marketbeat.comResearch Analysts Offer Predictions for MIRM FY2024 EarningsMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Leerink Partnrs upped their FY2024 earnings estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will post earJanuary 24, 2025 | marketbeat.comMirum Pharmaceuticals stock soars to all-time high of $48.94January 23, 2025 | msn.comMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High - Should You Buy?Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High - Still a Buy?January 23, 2025 | marketbeat.comCantor Fitzgerald Forecasts MIRM FY2025 EarningsMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Mirum Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($1.55) perJanuary 23, 2025 | marketbeat.comMirum Pharmaceuticals' chief medical officer sells $319,598 in stockJanuary 21, 2025 | msn.comJoanne Quan Sells 6,969 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) insider Joanne Quan sold 6,969 shares of the business's stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $45.86, for a total value of $319,598.34. Following the sale, the insider now owns 5,649 shares in the company, valued at approximately $259,063.14. The trade was a 55.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.January 21, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Acquires 29,545 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Hennion & Walsh Asset Management Inc. increased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 25.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 145,599 shares of the company's stJanuary 16, 2025 | marketbeat.comStrong Financial Performance and Strategic Positioning Lead to Buy Rating for Mirum PharmaceuticalsJanuary 16, 2025 | markets.businessinsider.comStrong Financial Performance and Strategic Growth Propel Mirum Pharmaceuticals to ‘Buy’ RatingJanuary 16, 2025 | markets.businessinsider.comBuy Recommendation for Mirum Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive OptimismJanuary 14, 2025 | markets.businessinsider.comMirum Pharmaceuticals: Strong Financial Performance and Promising Pipeline Support Buy RatingJanuary 14, 2025 | markets.businessinsider.comMirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Up 6% - Here's What HappenedMirum Pharmaceuticals (NASDAQ:MIRM) Shares Up 6% - Time to Buy?January 13, 2025 | marketbeat.comMirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate UpdatesJanuary 13, 2025 | businesswire.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 10, 2025 | businesswire.comJolanda Howe Sells 750 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockJanuary 9, 2025 | insidertrades.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of "Buy" by BrokeragesMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has earned a consensus rating of "Buy" from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the cJanuary 9, 2025 | marketbeat.comJolanda Howe Sells 750 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00. Following the sale, the senior vice president now directly owns 2,926 shares of the company's stock, valued at $125,291.32. This represents a 20.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.January 8, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 1,998 SharesMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) COO Peter Radovich sold 1,998 shares of the business's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the sale, the chief operating officer now owns 27,015 shares in the company, valued at $1,156,782.30. This trade represents a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.January 8, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 7,489 SharesMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the transaction, the chief executive officer now owns 119,359 shares of the company's stock, valued at $5,110,952.38. This represents a 5.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.January 8, 2025 | marketbeat.comTop 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)January 8, 2025 | seekingalpha.comMirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | businesswire.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC grew its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 3.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 936,197 shares of the company's stock after buying an additionalDecember 26, 2024 | marketbeat.comMirum Pharmaceuticals: Buy At Dips For Volixibat PotentialDecember 25, 2024 | seekingalpha.comState Street Corp Grows Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)State Street Corp increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 19.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,793,728 shares of the company's stock after buying aDecember 18, 2024 | marketbeat.comWellington Management Group LLP Raises Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Wellington Management Group LLP lifted its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 62.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,334 shares of the company's stock after purcDecember 17, 2024 | marketbeat.com741,368 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Bought by Lord Abbett & CO. LLCLord Abbett & CO. LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The fund acquired 741,368 shares of the company's stock, valued at approximately $28,913,000. Lord AbbeDecember 16, 2024 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Recommendation of "Buy" by BrokeragesMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has been given a consensus rating of "Buy" by the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation and two have given a strong buy rDecember 15, 2024 | marketbeat.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2024 | businesswire.com Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address MIRM Media Mentions By Week MIRM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIRM News Sentiment▼0.490.60▲Average Medical News Sentiment MIRM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIRM Articles This Week▼74▲MIRM Articles Average Week Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qiagen News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Revolution Medicines News Today Legend Biotech News Today BridgeBio Pharma News Today Axsome Therapeutics News Today Blueprint Medicines News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Elanco Animal Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIRM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIRM Stock Alerts